Bio-Techne Corp

TECH: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
Pt@LOCK|$<y$LOCK|z!&!v<>%

Bio-Techne Earnings: In-Line Results, Gradual Recovery in Fiscal 2025; Shares Modestly Undervalued

Narrow-moat Bio-Techne’s fourth-quarter earnings were in line with our expectations. Revenue was $306 million for the three months and $1.2 billion for the full year ended June 30, which both represented 1% organic year-over-year growth. We are maintaining our fair value estimate of $87 per share and view shares as modestly undervalued.

Sponsor Center